Tamoxifen has been associated with endometrial cancer proliferative effects and lymph node metastases in users, and this proliferative impact is driven by the GPER/EFGR/ERK/cyclin D1 pathway, which might be blocked by GPER silencing [172]. The gene discussed is GPER1; the disease is metastatic malignant neoplasm in the lymph nodes.